Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; citric acid; lactose monohydrate; mannitol; magnesium stearate; povidone; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; mannitol; pregelatinised maize starch; lactose monohydrate; citric acid; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ivermectin 3mg - tablet - 3 mg - active: ivermectin 3mg excipient: butylated hydroxyanisole citric acid magnesium stearate microcrystalline cellulose starch - · treatment of intestinal strongyloidiasis (anguillulosis). · treatment of proven suspected microfilaraemia in patients with lymphatic filariasis caused by wuchereria bancrofti. · treatment of human sarcoptic scabies after prior treatment has failed. treatment is justified when the diagnosis of scabies has been established clinically and/or by parasitological examination. without formal diagnosis, treatment is not justified in case of pruritus.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

maruho co.,ltd. - ivermectin - white tablet, diameter: 5.6mm, thickness: 2.0mm

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - norelgestromin (unii: r0tay3x631) (norelgestromin - unii:r0tay3x631), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (bmi) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. limitations of use: norelgestromin and ethinyl estradiol transdermal system may be less effective in preventing pregnancy in women who weigh 198 lbs (90 kg) or more. norelgestromin and ethinyl estradiol transdermal system is contraindicated for use in women with bmi ≥ 30 kg/m2 [see contraindications (4), warnings and precautions (5.1) and clinical studies (14) ]. norelgestromin and ethinyl estradiol transdermal system is contraindicated in females who are known to have or develop the following conditions: ●    at high risk of arterial or venous thromboembolic events. examples include women who: ○ smoke, if over age 35 [see boxed warning, and warnings and precautions (5.1)] ○ have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] ○ have inherited or acqui

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: gelatin; macrogol 4000; magnesium stearate; maize starch; lactose monohydrate; titanium dioxide; hypromellose - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: gelatin; hypromellose; iron oxide yellow; titanium dioxide; magnesium stearate; lactose monohydrate; maize starch; macrogol 4000 - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.